Theravance Biopharma (FRA:0TB) Market Cap : €428.14 Mil (As of May. 04, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Theravance Biopharma's share price for the quarter that ended in Dec. 2023 was €10.2. Theravance Biopharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 48.09 Mil. Therefore, Theravance Biopharma's market cap for the quarter that ended in Dec. 2023 was €490.53 Mil.

Theravance Biopharma's quarterly market cap declined from Jun. 2023 (€502.04 Mil) to Sep. 2023 (€398.93 Mil) but then increased from Sep. 2023 (€398.93 Mil) to Dec. 2023 (€490.53 Mil).

Theravance Biopharma's annual market cap declined from Dec. 2021 (€692.25 Mil) to Dec. 2022 (€678.36 Mil) and declined from Dec. 2022 (€678.36 Mil) to Dec. 2023 (€490.53 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Theravance Biopharma's Enterprise Value for Today is €378.50 Mil.

Theravance Biopharma Market Cap Historical Data

The historical data trend for Theravance Biopharma's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma Market Cap Chart

Theravance Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

1,311.35

926.32

692.25

678.36

490.53

Theravance Biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap	Get a 7-Day Free Trial															678.36	587.26	502.04	398.93	490.53

Competitive Comparison of Theravance Biopharma's Market Cap

For the Biotechnology subindustry, Theravance Biopharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theravance Biopharma's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Market Cap distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's Market Cap falls into.

Theravance Biopharma Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Theravance Biopharma's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	€10.2	*	48.091
	=	€490.53

Theravance Biopharma's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	€10.2	*	48.091
	=	€490.53

Theravance Biopharma (FRA:0TB) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Theravance Biopharma Market Cap Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Theravance Biopharma (FRA:0TB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (FRA:0TB) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

TBPH:USA

Address

Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104

Website

https://www.theravance.com

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma (FRA:0TB) Headlines

No Headlines